Drug intelligence / Profile preview

Pasteurized Akkermansia muciniphila LWHK0003

Development stage: Phase 1
Lead developer: Leeuwenhoek Laboratories
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Pasteurized Akkermansia muciniphila LWHK0003 (also known as NTUH_Amuc03) is a microbial therapeutic developed by Leeuwenhoek Laboratories Co. Ltd. for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD). Unlike live probiotics, this formulation consists of heat-killed (pasteurized) bacteria, which preserves key structural components such as the Amuc_1100 outer membrane protein. Its mechanism of action involves strengthening the intestinal barrier and modulating the gut-liver axis to reduce the translocation of pro-inflammatory pathogen-associated molecular patterns (PAMPs) and microbiota-derived metabolites (MDMs) from the gut to the liver. Preclinical studies in mice have demonstrated that LWHK0003 can attenuate fatty liver progression, reduce body weight, improve dyslipidemia, and enhance insulin sensitivity (HOMA-IR). It is currently being evaluated in Phase 1 clinical trials to assess its safety and efficacy in individuals with MASLD.

Other names: pasteurized Akkermansia muciniphilapAKK

Targets

TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on Pasteurized Akkermansia muciniphila LWHK0003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pasteurized Akkermansia muciniphila LWHK0003.

Explore the full profile